Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression

References

• Bannerji R, Byrd JC. Update on the biology of chronic lymphocytic leukemia. Curr Opin Oncol 2000;12:22–29.
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999;17:399–408.
   PubMed Web of Science ®Google Scholar
• Johnston J. Chronic lymphocytic leukemia. Wintrobe's clinical hematologyLee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, editors. Baltimore, MD: Williams and Wilkens,1999. 2405–2427.
   Google Scholar
• Bernal A, Pastore RD, Asgary Z, et al Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 2001;98:3050–3057.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655–2663.
   PubMed Web of Science ®Google Scholar
• Pedersen IM, Kitada S, Leoni LM, et al Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002;100:1795–1801.
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR, et al Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750–1757.
   PubMed Web of Science ®Google Scholar
• Jones DT, Ganeshaguru K, Anderson RJ, et al Albumin activates the AKT signaling pathway and protects B-chronic lymphocytic leukemia cells from chlorambucil- and radiation-induced apoptosis. Blood 2003;101:3174–3180.
   PubMed Web of Science ®Google Scholar
• Rosskopf D, Daelman W, Busch S, et al Growth factor-like action of lysophosphatidic acid on human B lymphoblasts. Am J Physiol 1998;274(6 Part 1):C1573–C1582.
   PubMedGoogle Scholar
• Hu X, Haney N, Kropp D, Kabore AF, Johnston JB, Gibson SB. Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB. J Biol Chem 2005;280:9498–9508.
   PubMed Web of Science ®Google Scholar
• Deng W, Balazs L, Wang DA, Van Middlesworth L, Tigyi G, Johnson LR. Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis. Gastroenterology 2002;123:206–216.
   PubMed Web of Science ®Google Scholar
• Deng W, Wang DA, Gosmanova E, Johnson LR, Tigyi G. LPA protects intestinal epithelial cells from apoptosis by inhibiting the mitochondrial pathway. Am J Physiol Gastrointest Liver Physiol 2003;284:G821–G829.
   PubMedGoogle Scholar
• Fang X, Yu S, LaPushin R, et al Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. Biochem J 2000;352(Part 1):135–143.
   PubMed Web of Science ®Google Scholar
• Goetzl EJ, Lee H, Dolezalova H, et al Mechanisms of lysolipid phosphate effects on cellular survival and proliferation. Ann NY Acad Sci 2000;905:177–187.
   PubMed Web of Science ®Google Scholar
• Iglesias J, Abernethy VE, Wang Z, Lieberthal W, Koh JS, Levine JS. Albumin is a major serum survival factor for renal tubular cells and macrophages through scavenging of ROS. Am J Physiol 1999;277(5 Part 2):F711–F722.
   PubMedGoogle Scholar
• Weiner JA, Chun J. Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid. Proc Natl Acad Sci USA 1999;96:5233–5238.
   PubMed Web of Science ®Google Scholar
• Harrison SM, Reavill C, Brown G, et al LPA(1) receptor-deficient mice have phenotypic changes observed in psychiatric disease. Mol Cell Neurosci 2003;24:1170–1179.
   PubMed Web of Science ®Google Scholar
• Takuwa Y, Takuwa N, Sugimoto N. The Edg family G protein-coupled receptors for lysophospholipids: their signaling properties and biological activities. J Biochem (Tokyo) 2002;131:767–771.
   PubMed Web of Science ®Google Scholar
• Fang X, Gaudette D, Furui T, et al Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann NY Acad Sci 2000;905:188–208.
   PubMed Web of Science ®Google Scholar
• Sardar VM, Bautista DL, Fischer DJ, et al Molecular basis for lysophosphatidic acid receptor antagonist selectivity. Biochim Biophys Acta 2002;1582(1–3):309–317.
   PubMed Web of Science ®Google Scholar
• Lee Z, Cheng CT, Zhang H, et al Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol Biol Cell 2008;19:5435–5445.
   PubMed Web of Science ®Google Scholar
• Lee CW, Rivera R, Gardell S, Dubin AE, Chun J. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 2006;281:23589–2397.
   PubMed Web of Science ®Google Scholar
• Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 2003;278:25600–25606.
   PubMed Web of Science ®Google Scholar
• Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J. Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci USA 2000;97:13384–13389.
   PubMed Web of Science ®Google Scholar
• Fukushima N, Chun J. The LPA receptors. Prostaglandins Other Lipid Mediat 2001;64:21–32.
   PubMed Web of Science ®Google Scholar
• Shida D, Kitayama J, Yamaguchi H, et al Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res 2003;63:1706–1711.
   PubMed Web of Science ®Google Scholar
• Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69(Suppl 3):4–10.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Kay NE. The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol 2006;33:174–185.
   PubMed Web of Science ®Google Scholar
• Kay NE. The angiogenic status of B-CLL B cells: role of the VEGF receptors. Leuk Res 2004;28:221–222.
   PubMed Web of Science ®Google Scholar
• Giles FJ. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies. Oncologist 2001;6(Suppl 5):32–39.
   PubMed Web of Science ®Google Scholar
• Molica S, Vitelli G, Levato D, Gandolfo GM, Liso V. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol 1999;107:605–610.
   PubMed Web of Science ®Google Scholar
• Farahani M, Treweeke AT, Toh CH, et al Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia 2005;19:524–530.
   PubMed Web of Science ®Google Scholar
• Ria R, Roccaro AM, Merchionne F, Vacca A, Dammacco F, Ribatti D. Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia 2003;17:1961–1966.
   PubMed Web of Science ®Google Scholar
• Gerber HP, Hillan KJ, Ryan AM, et al VEGF is required for growth and survival in neonatal mice. Development 1999;126:1149–1159.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–676.
   PubMed Web of Science ®Google Scholar
• Bairey O, Boycov O, Kaganovsky E, Zimra Y, Shaklai M, Rabizadeh E. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. Leuk Res 2004;28:243–248.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Mukhopadhyay D, Wu X, Kay NE. Neuropilin-1 is expressed by chronic lymphocytic leukemia B cells. Leuk Res 2008;32:1634–1636.
   PubMed Web of Science ®Google Scholar
• Lee J, Park SY, Lee EK, et al Activation of hypoxia-inducible factor-1{α} is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clin Cancer Res 2006;12:6351–6358.
   PubMed Web of Science ®Google Scholar
• Krejsgaard T, Vetter-Kauczok CS, Woetmann A, et al Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 2006;20:1759–1766.
   PubMed Web of Science ®Google Scholar
• Shibata A, Nagaya T, Imai T, Funahashi H, Nakao A, Seo H. Inhibition of NF-κB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat 2002;73:237–243.
   PubMed Web of Science ®Google Scholar
• Begleiter A, Verburg L, Ashique A, et al Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-β-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia 1995;9:1875–1881.
   PubMed Web of Science ®Google Scholar
• Johnston JB, Kabore AF, Strutinsky J, et al Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene 2003;22:8356–8369.
   PubMed Web of Science ®Google Scholar
• Oudijk EJ, Nijhuis EH, Zwank MD, et al Systemic inflammation in COPD visualised by gene profiling in peripheral blood neutrophils. Thorax 2005;60:538–544.
   PubMed Web of Science ®Google Scholar
• Gresch O, Engel FB, Nesic D, et al New non-viral method for gene transfer into primary cells. Methods 2004;33:151–163.
   PubMed Web of Science ®Google Scholar
• Hu YL, Tee MK, Goetzl EJ, et al Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 2001;93:762–768.
   PubMed Web of Science ®Google Scholar
• Hu X, Mendoza FJ, Sun J, Banerji V, Johnston JB, Gibson SB. Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies. Cell Signal 2008;20:1198–1208.
   PubMed Web of Science ®Google Scholar
• Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia 2005;19:513–523.
   PubMed Web of Science ®Google Scholar
• Forsythe JA, Jiang BH, Iyer NV, et al Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604–4613.
   PubMed Web of Science ®Google Scholar
• Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 2000;60:5879–5886.
   PubMed Web of Science ®Google Scholar
• Faderl S, Do KA, Johnson MM, et al Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood 2005;106:4303–4307.
   PubMed Web of Science ®Google Scholar
• de Gramont A, Tournigand C, Andre T, Larsen AK, Louvet C. Targeted agents for adjuvant therapy of colon cancer. Semin Oncol 2006;33(6 Suppl 11):S42–S45.
   PubMedGoogle Scholar
• Cardones AR, Banez LL. VEGF inhibitors in cancer therapy. Curr Pharm Des 2006;12:387–394.
   PubMed Web of Science ®Google Scholar
• Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004;104:788–794.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Lee YK, Call TG, et al Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res 2006;30:707–712.
   PubMed Web of Science ®Google Scholar
• Sasagawa T, Okita M, Murakami J, Kato T, Watanabe A. Abnormal serum lysophospholipids in multiple myeloma patients. Lipids 1999;34:17–21.
   PubMed Web of Science ®Google Scholar
• Xu Y, Shen Z, Wiper DW, et al Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. J Am Med Assoc 1998;280:719–723.
   PubMed Web of Science ®Google Scholar
• Frankel A, Mills GB. Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells. Clin Cancer Res 1996;2:1307–1313.
   PubMed Web of Science ®Google Scholar
• Kang YC, Kim KM, Lee KS, et al Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation. Cell Death Differ 2004;11:1287–1298.
   PubMed Web of Science ®Google Scholar
• Kingsbury MA, Rehen SK, Contos JJ, Higgins CM, Chun J. Non-proliferative effects of lysophosphatidic acid enhance cortical growth and folding. Nat Neurosci 2003;6:1292–1299.
   PubMed Web of Science ®Google Scholar